1. Home
  2. BRC vs DNLI Comparison

BRC vs DNLI Comparison

Compare BRC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brady Corporation

BRC

Brady Corporation

HOLD

Current Price

$83.93

Market Cap

4.1B

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$23.48

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRC
DNLI
Founded
1914
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.5B
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
BRC
DNLI
Price
$83.93
$23.48
Analyst Decision
Hold
Strong Buy
Analyst Count
1
14
Target Price
$1.20
$34.33
AVG Volume (30 Days)
420.4K
1.7M
Earning Date
05-15-2026
05-06-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,144,698,000.00
N/A
Revenue This Year
$7.36
N/A
Revenue Next Year
$3.57
$408.85
P/E Ratio
$23.35
N/A
Revenue Growth
5.86
N/A
52 Week Low
$65.76
$12.58
52 Week High
$99.29
$23.77

Technical Indicators

Market Signals
Indicator
BRC
DNLI
Relative Strength Index (RSI) 51.58 69.19
Support Level $73.44 $17.77
Resistance Level $88.72 $23.62
Average True Range (ATR) 3.58 1.10
MACD -0.09 0.32
Stochastic Oscillator 59.50 84.20

Price Performance

Historical Comparison
BRC
DNLI

About BRC Brady Corporation

Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: